Play Your Way to the Malta Poker Festival $500k GTD with Intertops Poker
26.7.2019 17:17:00 EEST | Business Wire | Press release
How do you fancy winning a place at the Malta Poker Festival €500,000 GTD? Intertops Poker is giving you a chance to win a seat at the table via a number of satellite tournaments starting on 29th July.
The Malta Poker Festival €500,000 GTD takes place from 30th October – 4th November 2019 and as one of the Intertops Poker satellite winners you will receive a truly VIP stay during the tournament and that all important chance to take home the top prize.
The satellite winner package is worth €2,500 and includes:
- Buy-in to the MPF main event, Day1C, November 1st
- 5-night stay for two in a luxury room at the Hilton 5* Malta Resort
- Tickets for the exclusive MPF VIP Player party
- $500 to help with travel expenses
- Dinner with the Intertops Poker Team
- Intertops Poker Gear
Satellite tournaments will take place on the following days and at the following times between 29th July and 4th August 2019.
Malta Poker Festival €500,000 GTD Step 1 $2+$0.20
Daily, starting July 29th to August 3rd
starting times: 6:10pm / 12:10am / 6:10am / 12:10pm (all times in EDT)
(12:10pm / 6:10pm / 12:10am / 6:10am - all times in CEST)
« 1 ticket for Malta Poker Festival €500,000 GTD Step 2 guaranteed! »
Malta Poker Festival €500,000 GTD Step 2 $10+$1
Daily, starting July 29th to August 4th
starting times: 7:10pm / 1:10am / 7:10am / 1:10pm (all times in EDT)
(1:10pm / 7:10pm / 1:10am / 7:10am - all times in CEST)
« 1 ticket for Malta Poker Festival €500,000 GTD Final guaranteed! »
Malta Poker Festival €500,000 GTD - 'ULTIMATE' - FREEROLL
Sunday, August 4th at 2am EDT (8am CEST)
« 1 ticket for Malta Poker Festival €500,000 GTD Final guaranteed! »
Malta Poker Festival €500,000 GTD - Last Chance I - $8+$0.80
Sunday, August 4th at 5am EDT (11am CEST)
« 1 ticket for Malta Poker Festival €500,000 GTD Final guaranteed! »
Malta Poker Festival €500,000 GTD - Last Chance II - $8+$0.80
Sunday, August 4th at 8am EDT (2pm CEST)
« 1 ticket for Malta Poker Festival €500,000 GTD Final guaranteed! »
Malta Poker Festival €500,000 GTD Satellite Final $100+$10
Sunday, August 4th at 1:10pm EDT (7:10pm CEST)
« 1x Malta Poker Festival €500,000 GTD package guaranteed! »
In addition, if you would like to keep up to speed with all the action from the European Poker Championship from Casino Velden in Austria you can follow our daily updates and coverage here.
ENDS
Editor’s notes:
About Intertops Poker:
Intertops Poker
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190726005317/en/
Contact information
GameOn Marketing
Sarah Blackburn | Director | GameOn
0034628499459
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom